Evidence map›Paper›PMID 42298213›Full record

ArticleEMBO molecular medicine2026

The Slr protein of Streptococcus pyogenes is selectively expressed in vivo and is a target for protective antibodies.

Matevž Rumpret, Jonas Lannergård, Bodil M Kristensen, Nicola N Lynskey, Connor Bowen, Eskil Johnsson, Olof R Nilsson, Anna Norrby-Teglund, Margaretha Stålhammar-Carlemalm, Gunnar Lindahl and 1 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matevž Rumpret *Centre for Bacterial Resistance Biology, Department of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-8631-8049
Jonas Lannergård *Division of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-9072-6486
Bodil M KristensenDivision of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0006-1024-1977
Nicola N LynskeyThe Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian, Scotland, UK.
Connor BowenThe Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian, Scotland, UK.
Eskil JohnssonDivision of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0005-7014-5437
Olof R NilssonDivision of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-0927-8052
Anna Norrby-TeglundCenter for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9372-1795
Margaretha Stålhammar-CarlemalmDivision of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Gunnar LindahlDivision of Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden. gunnar.lindahl@ple.lth.se.ORCID http://orcid.org/0000-0002-5734-1864
Alex J McCarthyCentre for Bacterial Resistance Biology, Department of Infectious Disease, Imperial College London, London, UK. a.mccarthy@imperial.ac.uk.ORCID http://orcid.org/0000-0002-4105-3737

Funding

Danish Strategic Research Council 09-067052Royal Society (The Royal Society) RGS\R1\201044Swedish Government Support for Clinical Research (ALF) ALFSKANE-193741UKRI | Biotechnology and Biological Sciences Research Council (AFRC) BBS/E/D/20002173UKRI | Biotechnology and Biological Sciences Research Council (AFRC) BB/V006495/1Vetenskapsrådet (VR) K2011-56X-09490-21-6Wellcome TrustWellcome Trust (WT) 225315/Z/22/Z
6 · The paper itself

Abstract

Vaccine candidates are typically identified through characterization of microbial surface antigens expressed under laboratory conditions. Here, we studied the major human pathogen Streptococcus pyogenes and showed that Slr, a lipoprotein encoded by all strains, is not detected on the bacterial surface during growth in broth but nevertheless is targeted by protective antibodies in vivo, as demonstrated by passive and active immunizations in a mouse model of invasive infection. The expression of Slr is governed by the zinc-controlled regulator AdcR, indicating that zinc depletion triggers surface expression of Slr in vivo. During infection in humans and mice, the antibody response to Slr is comparable to that elicited by the classical M protein and is, intriguingly, directed almost exclusively against a region with histidine triad (HT) motifs, an outcome that may represent a mechanism of immune escape. For vaccine development, these data focus interest on Slr and other microbial surface proteins selectively expressed in vivo.

Indexed as

Antibodies, BacterialBacterial ProteinsLipoproteinsStreptococcal InfectionsStreptococcus pyogenesAnimalsAntigens, BacterialHumansMiceAntibodies, BacterialAntigens, BacterialBacterial ProteinsLipoproteins

Identifiers

PMID42298213
PMCPMC13470328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.